Renin-angiotensin system blockers have been a cornerstone of hypertension management since the late 1980s. Angiotensin converting enzyme inhibitors, particularly lisinopril, are prescribed more frequently than angiotensin receptor blockers for several reasons. However, current data show similar efficacy between the two classes, with notable differences in terms of action duration, side effects, and costs. This article reviews the factors that may influence the choice between these treatments.
Devènes et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: